Pulmatrix (PULM) Competitors

Pulmatrix has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Pulmatrix's return on equity.

VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pulmatrix has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

In the previous week, Pulmatrix had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.89 beat Pulmatrix's score of 1.43 indicating that VYNE Therapeutics is being referred to more favorably in the media.

Pulmatrix has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

Pulmatrix has higher earnings, but lower revenue than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Pulmatrix, indicating that it is currently the more affordable of the two stocks.

Pulmatrix's return on equity of -107.84% beat Allarity Therapeutics' return on equity.

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 688.46%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Pulmatrix.

In the previous week, Pulmatrix and Pulmatrix both had 2 articles in the media. Pulmatrix's average media sentiment score of 1.43 equaled Allarity Therapeutics'average media sentiment score.

Pulmatrix has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Pulmatrix's return on equity.

11.8% of Pulmatrix shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 0.6% of Pulmatrix shares are held by insiders. Comparatively, 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pulmatrix has higher earnings, but lower revenue than Lipocine. Pulmatrix is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

In the previous week, Lipocine had 1 more articles in the media than Pulmatrix. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 1.43 beat Lipocine's score of 0.59 indicating that Pulmatrix is being referred to more favorably in the media.

Lipocine has a consensus price target of $15.00, indicating a potential upside of 509.76%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than Pulmatrix.

Pulmatrix has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

Pulmatrix has lower revenue, but higher earnings than Celularity. Pulmatrix is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

19.0% of Celularity shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 0.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pulmatrix has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Pulmatrix's return on equity.

Celularity has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Celularity currently has a consensus target price of $6.00, suggesting a potential upside of 867.74%. Given Celularity's stronger consensus rating and higher possible upside, analysts plainly believe Celularity is more favorable than Pulmatrix.

In the previous week, Pulmatrix had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for Celularity. Celularity's average media sentiment score of 1.89 beat Pulmatrix's score of 1.43 indicating that Celularity is being referred to more favorably in the media.